ITMI992711A0 - Composti organici - Google Patents
Composti organiciInfo
- Publication number
- ITMI992711A0 ITMI992711A0 IT99MI002711A ITMI992711A ITMI992711A0 IT MI992711 A0 ITMI992711 A0 IT MI992711A0 IT 99MI002711 A IT99MI002711 A IT 99MI002711A IT MI992711 A ITMI992711 A IT MI992711A IT MI992711 A0 ITMI992711 A0 IT MI992711A0
- Authority
- IT
- Italy
- Prior art keywords
- organic compounds
- compounds
- organic
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1999MI002711A ITMI992711A1 (it) | 1999-12-27 | 1999-12-27 | Composti organici |
TW089126229A TWI246917B (en) | 1999-12-27 | 2000-12-08 | Combinations of a receptor tyrosine kinase inhibitor with an organic compound capable of binding to alpha1-acidic glycoprotein |
AU21719/01A AU2171901A (en) | 1999-12-27 | 2000-12-22 | Combinations of a receptor tyrosine kinase inhibitor with an organic compound capable of binding to alpha1-acidic glycoprotein |
DE60042283T DE60042283D1 (de) | 1999-12-27 | 2000-12-22 | Kombination eines abl-, pdgf-rezeptor- und/oder kit rezeptor-tyrosin kinase inhibitors mit einer organischen substanz, die an alpha1-acidisches glycoprotein bindet |
BR0016817-3A BR0016817A (pt) | 1999-12-27 | 2000-12-22 | Combinações de um inibidor de quinase do receptor de tirosina com um composto orgânico capaz de se ligar à alfa1-glicoproteìna ácida |
AT00985244T ATE432069T1 (de) | 1999-12-27 | 2000-12-22 | Kombination eines abl-, pdgf-rezeptor- und/oder kit rezeptor-tyrosin kinase inhibitors mit einer organischen substanz, die an alpha1-acidisches glycoprotein bindet |
PCT/EP2000/013161 WO2001047507A2 (en) | 1999-12-27 | 2000-12-22 | Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound |
CA002394944A CA2394944A1 (en) | 1999-12-27 | 2000-12-22 | Combinations of a receptor tyrosine kinase inhibitor with an organic compound capable of binding to .alpha.1-acidic glycoprotein |
CO00097404A CO5271710A1 (es) | 1999-12-27 | 2000-12-22 | Combinanciones de un inhibidor de cinasa de tirosina receptora con un compuesto organico capaz de enlazarse con glicorpoteina acido-a |
PE2000001393A PE20010991A1 (es) | 1999-12-27 | 2000-12-22 | Combinaciones de un inhibidor de cinasa de tirosina receptora con un compuesto organico capaz de enlazarse con glicoproteina acido-o1 |
CNB008178976A CN1304005C (zh) | 1999-12-27 | 2000-12-22 | 受体酪氨酸激酶抑制剂和α1-酸性糖蛋白结合化合物的联合形式 |
ARP000106887A AR030179A1 (es) | 1999-12-27 | 2000-12-22 | Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceutico |
US10/169,035 US20030125343A1 (en) | 1999-12-27 | 2000-12-22 | Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound |
EP00985244A EP1250140B1 (en) | 1999-12-27 | 2000-12-22 | Combination ofan abl-, pdgf-receptor- and/or kit receptor-tyrosine kinase inhibitor with an organic compound capable of binding to alpha1-acidic glycoprotein |
JP2001548102A JP2003523325A (ja) | 1999-12-27 | 2000-12-22 | 受容体チロシンキナーゼ阻害剤とα1−酸性糖タンパク質結合性有機化合物との組合せ |
PT00985244T PT1250140E (pt) | 1999-12-27 | 2000-12-22 | Combinação de um inibidor de abl, receptor pdgf e/ou receptor kit-tirosina quinase com um composto orgânico capaz de se ligar a uma alfa1-glicoproteína ácida |
ES00985244T ES2326307T3 (es) | 1999-12-27 | 2000-12-22 | Combinacion de un inhibidor del receptor abl, receptor pdgf y/o receptor de kit de la tirosina quinasa con un compuesto organico capaz de unirse a la glicoproteina acida-alfa1. |
HK03101801.4A HK1050993A1 (zh) | 1999-12-27 | 2003-03-12 | 受體酪氨酸激酶抑制劑與能夠結合a1-酸的糖蛋白的有機化合物的組合 |
US12/397,374 US20090221519A1 (en) | 1999-12-27 | 2009-03-04 | Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1999MI002711A ITMI992711A1 (it) | 1999-12-27 | 1999-12-27 | Composti organici |
Publications (2)
Publication Number | Publication Date |
---|---|
ITMI992711A0 true ITMI992711A0 (it) | 1999-12-27 |
ITMI992711A1 ITMI992711A1 (it) | 2001-06-27 |
Family
ID=11384195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT1999MI002711A ITMI992711A1 (it) | 1999-12-27 | 1999-12-27 | Composti organici |
Country Status (18)
Country | Link |
---|---|
US (2) | US20030125343A1 (it) |
EP (1) | EP1250140B1 (it) |
JP (1) | JP2003523325A (it) |
CN (1) | CN1304005C (it) |
AR (1) | AR030179A1 (it) |
AT (1) | ATE432069T1 (it) |
AU (1) | AU2171901A (it) |
BR (1) | BR0016817A (it) |
CA (1) | CA2394944A1 (it) |
CO (1) | CO5271710A1 (it) |
DE (1) | DE60042283D1 (it) |
ES (1) | ES2326307T3 (it) |
HK (1) | HK1050993A1 (it) |
IT (1) | ITMI992711A1 (it) |
PE (1) | PE20010991A1 (it) |
PT (1) | PT1250140E (it) |
TW (1) | TWI246917B (it) |
WO (1) | WO2001047507A2 (it) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2427184A1 (en) * | 2000-11-22 | 2002-05-30 | Novartis Ag | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
AU2002315388A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel phenylamino-pyrimidines and uses thereof |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
US7323469B2 (en) | 2001-08-07 | 2008-01-29 | Novartis Ag | 7H-pyrrolo[2,3-d]pyrimidine derivatives |
DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
NZ532418A (en) * | 2001-10-25 | 2007-02-23 | Novartis Ag | Combinations comprising a selective cyclooxygenase-2 inhibitor and a microtubule interfering agent |
GB0201508D0 (en) | 2002-01-23 | 2002-03-13 | Novartis Ag | Organic compounds |
EP1487451A4 (en) * | 2002-03-21 | 2007-10-03 | Dana Farber Cancer Inst Inc | INHIBITION OF CELLULAR DEATH RESPONSES INDUCED BY OXIDATIVE STRESS |
AU2007201830C1 (en) * | 2002-04-23 | 2017-09-07 | Novartis Pharma Ag | High drug load tablet |
GB0209265D0 (en) * | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
AU2003295320A1 (en) * | 2002-06-26 | 2004-04-08 | The Ohio State University Research Foundation | The method for reducing inflammation using sti-571 or its salt |
AU2003232376A1 (en) * | 2002-07-24 | 2004-02-09 | Novartis Ag | 4-(4-methylpiperazin-1-ylmethyl)-n-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating anaplastic thyroid cancer |
AU2003250701A1 (en) * | 2002-07-31 | 2004-02-16 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
GB0222514D0 (en) | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
WO2004033446A1 (en) * | 2002-10-09 | 2004-04-22 | Danter Wayne R | Protein tyrosine kinase inhibitors |
JP2007523827A (ja) * | 2003-08-25 | 2007-08-23 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 混合性白血病遺伝子の再構成を伴う急性リンパ芽球性白血病の処置方法 |
ATE489109T1 (de) * | 2003-09-19 | 2010-12-15 | Novartis Pharma Gmbh | Behandlung von gastrointestinalen stromatumoren mit imatinib und midostaurin |
TW200517114A (en) * | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
SI1720853T1 (sl) † | 2004-02-11 | 2016-04-29 | Natco Pharma Limited "Natco House | Nova polimorfna oblika imatinibijevega mesilata in postopek za njeno pripravo |
EP1768982A2 (en) | 2004-06-29 | 2007-04-04 | Amgen Inc. | Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity |
WO2006017443A2 (en) * | 2004-08-02 | 2006-02-16 | Osi Pharmaceuticals, Inc. | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds |
AU2005322855B2 (en) | 2004-12-30 | 2012-09-20 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
US20060275365A1 (en) * | 2005-06-07 | 2006-12-07 | Thomas Backensfeld | Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof |
US20070059359A1 (en) * | 2005-06-07 | 2007-03-15 | Thomas Backensfeld | Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof |
WO2006136391A2 (en) * | 2005-06-23 | 2006-12-28 | Novartis Ag | Treatment of solid tumor disease with combinations comprising imatinib and an efflux pump inhibitor |
WO2007076035A2 (en) * | 2005-12-21 | 2007-07-05 | Abbott Laboratories | Anti-viral compounds |
RU2441869C2 (ru) * | 2005-12-21 | 2012-02-10 | Эбботт Лэборетриз | Противовирусные соединения |
WO2007081517A2 (en) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
WO2007124369A2 (en) * | 2006-04-20 | 2007-11-01 | Janssen Pharmaceutica N.V. | Method of inhibiting c kit kinase |
AU2007269540B2 (en) * | 2006-07-05 | 2013-06-27 | Exelixis, Inc. | Methods of using IGF1R and Abl kinase modulators |
WO2008133753A2 (en) | 2006-12-20 | 2008-11-06 | Abbott Laboratories | Anti-viral compounds |
US8034815B2 (en) | 2007-01-11 | 2011-10-11 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
US20080248548A1 (en) * | 2007-04-09 | 2008-10-09 | Flynn Daniel L | Modulation of protein functionalities |
BRPI0817946A2 (pt) * | 2007-09-25 | 2015-05-05 | Teva Pharma | Composições de imatinibe estável |
EP2225226B1 (en) | 2007-12-26 | 2016-08-17 | Critical Outcome Technologies, Inc. | Compounds and their use in a method for treatment of cancer |
BRPI0906475A2 (pt) | 2008-01-11 | 2015-07-14 | Natco Pharma Ltd | Compostos, processso para a preparação de um composto, composição farmacêutica e uso de um composto |
DK2300013T3 (en) | 2008-05-21 | 2017-12-04 | Ariad Pharma Inc | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
EP2318406B1 (en) | 2008-07-17 | 2016-01-27 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
CA2744563A1 (en) | 2008-12-12 | 2010-06-17 | Ariad Pharmaceuticals, Inc. | Azaindole derivatives as kinase inhibitors |
ITRM20090578A1 (it) * | 2009-11-10 | 2011-05-11 | Noi Per Voi Onlus | Nuove composizioni per il trattamento di leucemie chemioresistenti e/o di leucemie potenzialmente chemioresistenti. |
CA2999435A1 (en) | 2010-04-01 | 2011-10-06 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
AR083797A1 (es) | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
TR201010618A2 (tr) * | 2010-12-20 | 2012-07-23 | Bi̇lgi̇ç Mahmut | İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi |
PL394169A1 (pl) | 2011-03-09 | 2012-09-10 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania |
CN103501612B (zh) | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物 |
EP2817030A1 (en) | 2012-02-21 | 2014-12-31 | Ranbaxy Laboratories Limited | Stable dosage forms of imatinib mesylate |
US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
WO2017078647A1 (en) | 2015-11-05 | 2017-05-11 | Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi | Pharmaceutical compositions of imatinib |
EP3257499A1 (en) | 2016-06-17 | 2017-12-20 | Vipharm S.A. | Process for preparation of imatinib methanesulfonate capsules |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5587459A (en) * | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
US5750493A (en) * | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
US20030069174A1 (en) * | 1997-03-10 | 2003-04-10 | Ludwig Pichler | Use of human alpha1-acid glycoprotein for producing a pharmaceutical preparation |
CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
WO2001004125A1 (fr) * | 1999-07-13 | 2001-01-18 | Kyowa Hakko Kogyo Co., Ltd. | Derives de staurosporine |
EE05351B1 (et) * | 1999-12-10 | 2010-10-15 | Pfizer Products Inc. | Prrolo[2,3-d]primidiinhendid |
-
1999
- 1999-12-27 IT IT1999MI002711A patent/ITMI992711A1/it unknown
-
2000
- 2000-12-08 TW TW089126229A patent/TWI246917B/zh active
- 2000-12-22 AU AU21719/01A patent/AU2171901A/en not_active Abandoned
- 2000-12-22 JP JP2001548102A patent/JP2003523325A/ja active Pending
- 2000-12-22 CO CO00097404A patent/CO5271710A1/es not_active Application Discontinuation
- 2000-12-22 WO PCT/EP2000/013161 patent/WO2001047507A2/en active Search and Examination
- 2000-12-22 ES ES00985244T patent/ES2326307T3/es not_active Expired - Lifetime
- 2000-12-22 DE DE60042283T patent/DE60042283D1/de not_active Expired - Lifetime
- 2000-12-22 EP EP00985244A patent/EP1250140B1/en not_active Expired - Lifetime
- 2000-12-22 CN CNB008178976A patent/CN1304005C/zh not_active Expired - Fee Related
- 2000-12-22 AR ARP000106887A patent/AR030179A1/es not_active Application Discontinuation
- 2000-12-22 US US10/169,035 patent/US20030125343A1/en not_active Abandoned
- 2000-12-22 CA CA002394944A patent/CA2394944A1/en not_active Abandoned
- 2000-12-22 PT PT00985244T patent/PT1250140E/pt unknown
- 2000-12-22 AT AT00985244T patent/ATE432069T1/de active
- 2000-12-22 PE PE2000001393A patent/PE20010991A1/es not_active Application Discontinuation
- 2000-12-22 BR BR0016817-3A patent/BR0016817A/pt not_active Application Discontinuation
-
2003
- 2003-03-12 HK HK03101801.4A patent/HK1050993A1/zh unknown
-
2009
- 2009-03-04 US US12/397,374 patent/US20090221519A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1414858A (zh) | 2003-04-30 |
DE60042283D1 (de) | 2009-07-09 |
HK1050993A1 (zh) | 2003-07-18 |
AR030179A1 (es) | 2003-08-13 |
ITMI992711A1 (it) | 2001-06-27 |
CN1304005C (zh) | 2007-03-14 |
WO2001047507A3 (en) | 2002-04-04 |
US20090221519A1 (en) | 2009-09-03 |
EP1250140B1 (en) | 2009-05-27 |
ATE432069T1 (de) | 2009-06-15 |
BR0016817A (pt) | 2002-10-01 |
JP2003523325A (ja) | 2003-08-05 |
AU2171901A (en) | 2001-07-09 |
US20030125343A1 (en) | 2003-07-03 |
TWI246917B (en) | 2006-01-11 |
EP1250140A2 (en) | 2002-10-23 |
CA2394944A1 (en) | 2001-07-05 |
WO2001047507A2 (en) | 2001-07-05 |
PT1250140E (pt) | 2009-08-24 |
CO5271710A1 (es) | 2003-04-30 |
PE20010991A1 (es) | 2001-10-23 |
ES2326307T3 (es) | 2009-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ITMI992711A0 (it) | Composti organici | |
NO20026253L (no) | Organiske forbindelser | |
NO20004299L (no) | Organiske forbindelser | |
EE200100502A (et) | Ühendid | |
PT1202994E (pt) | Novos compostos | |
NO20021637L (no) | Kjemikalske forbindelser | |
NO20016115L (no) | Substituerte heterosykelkondenserte gamma-karbolin | |
PT1224180E (pt) | Azois substituidos | |
EE200200224A (et) | Uudsed ühendid | |
IS6139A (is) | Ný efnasambönd | |
DE60040978D1 (de) | Bakterizides organisches polymermaterial | |
NO20013769D0 (no) | Kalsilytiske forbindelser | |
DE60003361T2 (de) | Elektrolumineszenzlampe | |
NO20020466D0 (no) | Kalsilytiske forbindelser | |
IS6141A (is) | Ný efnasambönd | |
NO20014262D0 (no) | Tiazoloindolinon-forbindelser | |
NO20022927D0 (no) | Substituerte pyrrazoler | |
ATE251154T1 (de) | Substituierte phenyluracile | |
ID29984A (id) | Senyawa-senyawa bis-stirilbifenil | |
NO20013530D0 (no) | Organbeskyttende lösninger | |
SE9904418D0 (sv) | New compounds | |
SE9904422D0 (sv) | New compounds | |
SE9900086D0 (sv) | New compounds | |
SE9900071D0 (sv) | New compounds | |
SE9902762D0 (sv) | New compounds |